Vanguard Group Inc Y M Abs Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,035,363 shares of YMAB stock, worth $16.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,035,363
Previous 1,957,339
3.99%
Holding current value
$16.9 Million
Previous $23.6 Million
13.03%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding YMAB
# of Institutions
106Shares Held
24.5MCall Options Held
40.3KPut Options Held
400-
Paradigm Biocapital Advisors LP New York, NY4.09MShares$33.8 Million1.93% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$24.3 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$18.2 Million2.73% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$15.2 Million0.15% of portfolio
-
Cormorant Asset Management, LP Boston, MA1.45MShares$12 Million1.33% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $362M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...